Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma

PURPOSE: Benralizumab is a monoclonal antibody that targets the α subunit of the IL-5 receptor. Clinical trials have demonstrated the efficacy of this agent with respect to lung function and symptom control in patients with refractory eosinophilic asthma. However, few studies have evaluated the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Bastero Fernández, Ana, Medina Gallardo, Juan Francisco, Delgado Romero, Julio, Romero Falcón, Auxiliadora, Benito Bernáldez, Cristina, Gallego Borrego, Javier, Álvarez-Gutiérrez, Francisco Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148608/
https://www.ncbi.nlm.nih.gov/pubmed/35642210
http://dx.doi.org/10.2147/JAA.S358705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148608/
https://www.ncbi.nlm.nih.gov/pubmed/35642210
http://dx.doi.org/10.2147/JAA.S358705

Ejemplares similares